Greg Jones
Company: Pfizer
Job title: Principal Scientist
Seminars:
Targeting RAF Kinases to Overcome Adaptive Resistance to RAS Targeted Therapies 9:00 am
Clinical and pre-clinical data emphasizes the frequency of on-target and onpathway (ERK-MAPK) adaptive and acquired resistance mechanisms to KRASG12C targeted therapies. CRISPR LoF screens in KRAS-G12C inhibitor resistant cell lines reveal gene subsets whose depletion restores sensitivity to KRASG12C inhibitor treatment. RAF kinases, notably CRAF, was uncovered as one such gene. CRISPR genetic ablation and…Read more
day: Day Two